Detail akcie Halozyme Thrp online

Business Summary: Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Halozyme Therapeutics, Inc. revenues increased 22% to $1.02B. Net income increased 58% to $444.1M. Revenues reflect Royalties segment increase of 27% to $571M, Hylenex segment increase of 27% to $166.6M, United States segment increase of 18% to $690.5M, Switzerland segment increase of 43% to $212.4M. Net income benefited from Investment and other income increase of 46% to $23.8M (income), Selling.